Community Ophthalmology Practice Questions

Q: What does the 'S' in the "SAFE" strategy for the control of trachoma stand for?

Surgery. The **SAFE strategy** is a comprehensive public health approach developed by the World Health Organization (WHO) to eliminate **Trachoma** (caused by *Chlamydia trachomatis*) as a cause of blindness. ### **Explanation of the Correct Answer** The correct answer is **Surgery**. The 'S' stands for surgery to correct **Trachomatous Trichiasis (TT)**. This is the immediate clinical intervention required to prevent corneal scarring and permanent blindness in individuals where the disease has already progressed to the stage of in-turned eyelashes. The full acronym stands for: * **S: Surgery** (for Trichiasis) * **A: Antibiotics** (Mass Drug Administration of Oral Azithromycin) * **F: Facial cleanliness** (to reduce transmission) * **E: Environmental improvement** (access to water and sanitation) ### **Why Other Options are Incorrect** * **Safety:** While patient safety is a general medical principle, it is not a specific component of the WHO trachoma elimination protocol. * **Solutions:** This is a vague term; while antibiotic solutions (eye drops) were used historically, the current strategy focuses on systemic antibiotics (Azithromycin). * **Side-effects:** Monitoring side effects is part of any pharmacological treatment, but it is not a pillar of the community-based SAFE strategy. ### **High-Yield Clinical Pearls for NEET-PG** * **Target:** The goal is the Global Elimination of Trachoma by **2030**. * **Drug of Choice:** A single dose of **Oral Azithromycin (20 mg/kg)** is the mainstay of the 'A' component. Tetracycline eye ointment (1%) is an alternative. * **Surgical Procedure:** The preferred surgery for trichiasis is **Bilamellar Tarsal Rotation (BTR)**. * **Vector:** The common housefly (**Musca sorbens**) is the primary vector for transmission. * **WHO Grading:** Remember the **FISTO** classification (Follicular, Intense, Scarring, Trichiasis, Opacity) for clinical staging.

Q: When should screening for Diabetic Retinopathy be initiated after the diagnosis of diabetes?

Type 2 DM: Immediately. ### Explanation The timing of screening for Diabetic Retinopathy (DR) is based on the likely duration of hyperglycemia prior to clinical diagnosis. **1. Why "Type 2 DM: Immediately" is correct:** In Type 2 Diabetes Mellitus (T2DM), the onset of hyperglycemia is often insidious and asymptomatic. Patients may have had undiagnosed diabetes for several years before a clinical diagnosis is made. Consequently, approximately **20% of T2DM patients** already have some degree of retinopathy at the time of diagnosis. Therefore, screening must be performed **immediately (at the time of diagnosis)** to detect existing microvascular damage. **2. Why the other options are incorrect:** * **Options B & C (Within 6 months/1 year):** Waiting for 6 months or a year is unsafe for T2DM patients, as sight-threatening proliferative changes or macular edema could progress during this delay. * **Option D (Type 1 DM: Within one week):** This is incorrect because Type 1 DM has an acute onset. Retinopathy rarely develops within the first few years of the disease. Screening for Type 1 DM is typically initiated **5 years after diagnosis** (or at puberty). **3. Clinical Pearls for NEET-PG:** * **Follow-up Frequency:** If no retinopathy is found, screening is generally repeated **annually**. * **Pregnancy:** Diabetic women who become pregnant should have an eye exam in the **first trimester** and be monitored closely throughout pregnancy, as DR can progress rapidly. (Note: This does not apply to Gestational Diabetes). * **First Sign of DR:** The earliest clinical sign is **Microaneurysms** (found in the Inner Nuclear Layer). * **Earliest Pathological Change:** Loss of **pericytes** and basement membrane thickening. * **Screening Tool:** The gold standard for screening is **7-standard field stereoscopic fundus photography**.

Q: What eye condition was the focus of the National Programme for Control of Blindness, supported by World Bank assistance from 1994-2001?

Cataract. **Explanation:** The **National Programme for Control of Blindness (NPCB)**, launched in 1976, underwent a significant shift in strategy during the 1990s. From **1994 to 2001**, the World Bank-assisted **Cataract Blindness Control Project** was implemented. The primary objective was to reduce the massive backlog of cataract cases in India, which accounted for approximately 80% of avoidable blindness at the time. This period saw the transition from conventional intracapsular cataract extraction (ICCE) to extracapsular cataract extraction with **Intraocular Lens (IOL) implantation**, alongside the establishment of District Blindness Control Societies (DBCS). **Analysis of Options:** * **B. Refractive errors:** While a major cause of visual impairment, it became a primary focus of the NPCB only in later phases (post-2001) under the "Vision 2020: The Right to Sight" initiative. * **C. Trachoma:** This was the focus of the initial National Trachoma Control Programme (1963), which was later merged into the NPCB. By 1994, its prevalence had significantly declined. * **D. Vitamin A deficiency:** This is primarily addressed through the National Prophylaxis Programme against Nutritional Blindness (Ministry of Health and Family Welfare), focusing on periodic high-dose supplementation for children. **High-Yield Clinical Pearls for NEET-PG:** * **Current Status:** The NPCB is now known as the National Programme for Control of Blindness and Visual Impairment (NPCBVI). * **Leading Cause of Blindness in India:** Cataract (66.2%), followed by Refractive Errors (18.6%). * **Definition of Blindness (WHO/NPCB):** Visual acuity <3/60 in the better eye with best possible correction. * **Target:** The current goal is to reduce the prevalence of blindness to **0.25% by 2025**.

Q: What was the goal of the National Programme for Control of Blindness (NPCB) regarding the prevalence of blindness?

To reduce it to less than 0.3% by the year 2000. **Explanation:** The **National Programme for Control of Blindness (NPCB)** was launched in 1976 as a 100% Centrally Sponsored scheme. Its primary objective was to reduce the prevalence of blindness in India from the then-estimated **1.4% to less than 0.3% by the year 2000**. This target was set to align with the global "Health for All" initiative. * **Why Option A is Correct:** The original mandate of the NPCB specifically aimed for the 0.3% target by the turn of the millennium. Although this target was not fully achieved by 2000 (prevalence was ~1.1% in 2001-02), it remains the landmark historical goal frequently tested in exams. * **Why Options B, C, and D are Incorrect:** These years and percentages represent later revisions or different phases of the program. For instance, under **Vision 2020: The Right to Sight**, the revised target was to reduce the prevalence to **0.3% by the year 2020**. Currently, under the 12th Five-Year Plan and subsequent updates, the goal is to reduce it to **0.25%**. **High-Yield Clinical Pearls for NEET-PG:** * **Current Prevalence:** According to the National Blindness and Visual Impairment Survey (2015-19), the prevalence of blindness in India has reduced to **0.36%**. * **Definition Change:** NPCB recently aligned its definition of blindness with WHO criteria: **Visual acuity <3/60** in the better eye with best possible correction (previously it was <6/60). * **Leading Cause:** **Cataract** remains the leading cause of blindness in India (approx. 66.2%), followed by corneal opacity and glaucoma. * **Target Group:** The program focuses heavily on the 50+ age group, where the prevalence of avoidable blindness is highest.

Q: The mass treatment of trachoma is undertaken if the prevalence in the community is:

5%. **Explanation:** The management of Trachoma (caused by *Chlamydia trachomatis*) follows the WHO-recommended **SAFE Strategy** (Surgery, Antibiotics, Facial cleanliness, and Environmental improvement). The decision to initiate community-wide mass treatment depends on the prevalence of **Trachomatous Inflammation—Follicular (TF)** in children aged 1–9 years. **Why 5% is the Correct Answer:** According to the current WHO guidelines, mass drug administration (MDA) with oral Azithromycin is indicated if the prevalence of TF in children (1–9 years) is **≥ 5%**. * If prevalence is **5% to <10%**, a single round of annual mass treatment is conducted, followed by a re-impact survey. * If prevalence is **≥ 10%**, annual mass treatment is mandatory for at least 3 years before re-evaluation. **Analysis of Incorrect Options:** * **A (3%):** This is below the threshold for mass intervention. At this level, treatment is usually targeted at individual cases and their household contacts rather than the whole community. * **C (6%):** While 6% qualifies for mass treatment, the **threshold** for initiating the program is 5%. In competitive exams, the minimum cutoff value is the standard answer. * **D (10%):** This was the historical threshold for mass treatment in older guidelines. However, the WHO updated the criteria to 5% to accelerate the elimination of blinding trachoma. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Single dose of **Oral Azithromycin (20 mg/kg up to 1g)**. Topical 1% Tetracycline eye ointment is an alternative. * **WHO Target:** The goal is the **Elimination of Trachoma as a public health problem**, defined as a TF prevalence of 15 years). * **SAFE Strategy:** "S" and "A" are the medical/surgical components, while "F" and "E" are the public health components.

Q: Minimum visual acuity below which a person is considered blind is:

6/18. **Explanation:** The correct answer is **6/18**. This definition aligns with the **National Programme for Control of Blindness (NPCB)** in India, which recently revised its criteria to synchronize with the World Health Organization (WHO) standards. **1. Why 6/18 is Correct:** Under the revised NPCB guidelines, blindness is defined as visual acuity **less than 3/60** in the better eye with best possible correction. However, the question asks for the threshold **below which** a person is considered to have a visual impairment/blindness category. In the context of "Social Blindness" or the screening criteria used in India, a person is considered "blind" for program purposes if their vision is **< 6/18** in the better eye. This change was implemented to increase the coverage of eye care services and identify individuals needing intervention earlier. **2. Analysis of Incorrect Options:** * **6/60 (Option A):** This was the **previous NPCB definition** of blindness. It is now considered the threshold for "Severe Visual Impairment" (vision < 6/60 to 3/60). * **6/6 (Option C):** This represents normal visual acuity. * **6/12 (Option D):** This is a threshold often used for fitness in specific occupations (like driving) but is not the standard definition for blindness in community ophthalmology. **High-Yield Clinical Pearls for NEET-PG:** * **WHO Definition of Blindness:** Visual acuity < 3/60 or a visual field less than 10° in the better eye. * **Low Vision:** Visual acuity between < 6/18 and 3/60. * **Economic Blindness:** Vision < 6/60 (prevents a person from earning a living). * **One-eyed person:** If the other eye has vision < 3/60, the person is considered blind. * **Most common cause of blindness in India:** Cataract (followed by Refractive Errors).

Q: Mass treatment with azithromycin is indicated if the prevalence of follicular trachomatous inflammation (TF) in the 1-9 years population is more than:

10%. This question pertains to the **WHO SAFE Strategy** for the elimination of blinding trachoma. Trachoma is caused by *Chlamydia trachomatis* (serotypes A, B, Ba, and C), and community-wide intervention is triggered based on the prevalence of active disease in children. ### **Explanation of the Correct Answer** According to the latest WHO guidelines, **Mass Drug Administration (MDA)** with oral Azithromycin is indicated when the prevalence of **Trachomatous inflammation—Follicular (TF)** in children aged **1–9 years** is **≥ 10%**. * **The Goal:** To reduce the community reservoir of infection. * **The Protocol:** If TF ≥ 10%, the entire district/community receives annual mass treatment for at least 3 years before re-surveying. ### **Analysis of Incorrect Options** * **A, B, and C (4%, 6%, 8%):** These values do not meet the WHO threshold for mass treatment. However, it is important to note that if the prevalence is **between 5% and 9.9%**, the WHO recommends targeted treatment (treating households or sub-districts) rather than district-wide MDA. If the prevalence is **< 5%**, mass treatment is generally not required, and the focus shifts to clinical surveillance. ### **High-Yield Clinical Pearls for NEET-PG** * **SAFE Strategy:** **S**urgery (for Trichiasis), **A**ntibiotics (Azithromycin), **F**acial cleanliness, **E**nvironmental improvement. * **Drug of Choice:** A single dose of **Oral Azithromycin (20 mg/kg up to 1g)** is the gold standard for MDA. Topical 1% Tetracycline eye ointment (twice daily for 6 weeks) is an alternative if Azithromycin is contraindicated. * **WHO Grading (FISTO):** 1. **TF** (Follicular): >5 follicles of >0.5mm. 2. **TI** (Intense): Thickening obscuring >50% of deep tarsal vessels. 3. **TS** (Scarring). 4. **TT** (Trichiasis): At least one lash rubbing the eyeball. 5. **CO** (Corneal Opacity). * **Elimination Target:** Prevalence of TF < 5% in children aged 1–9 years.

Q: Mobile eye clinics are an example of which level of prevention?

Secondary Prevention. **Explanation:** The correct answer is **Secondary Prevention**. **1. Why it is Secondary Prevention:** The core objective of secondary prevention is **early diagnosis and prompt treatment** to arrest the disease process and prevent complications. Mobile eye clinics (such as those organized under the National Programme for Control of Blindness) function as screening units. They travel to underserved areas to identify existing cases of refractive errors, cataracts, or glaucoma and provide immediate interventions (e.g., prescribing glasses or referring for surgery). Since the disease is already present but detected early through screening, it falls under secondary prevention. **2. Why other options are incorrect:** * **Primordial Prevention:** Focuses on preventing the emergence of risk factors (e.g., improving socio-economic status or health education to prevent childhood obesity). * **Primary Prevention:** Aims to prevent the onset of disease by altering susceptibility or reducing exposure (e.g., Vitamin A supplementation to prevent xerophthalmia or wearing UV-protective goggles). * **Tertiary Prevention:** Focuses on limiting disability and rehabilitation after a disease has caused permanent damage (e.g., low-vision aids for the legally blind or keratoplasty for corneal scarring). **3. High-Yield NEET-PG Pearls:** * **Screening** of any kind is always **Secondary Prevention**. * **School Eye Screening** programs are a classic example of secondary prevention aimed at detecting refractive errors. * **Vitamin A prophylaxis** is **Primary Prevention** (Specific Protection). * **Trachoma control (SAFE strategy):** 'S' (Surgery) is Secondary/Tertiary, while 'A', 'F', and 'E' (Antibiotics, Facial cleanliness, Environmental change) are Primary Prevention.

Question 1

What does the 'S' in the "SAFE" strategy for the control of trachoma stand for?

Accepted Answer

Surgery

Answer

Safety

Answer

Solutions

Answer

Side-effects

Question 2

What is true about economic blindness?

Accepted Answer

The level of blindness that prevents an individual from earning their wages.

Answer

Blindness that is costly to treat.

Answer

Both option 1 and option 2.

Answer

None of the above.

Question 3

When should screening for Diabetic Retinopathy be initiated after the diagnosis of diabetes?

Accepted Answer

Type 2 DM: Immediately

Answer

Type 2 DM: Within 6 months

Answer

Type 2 DM: Within 1 year

Answer

Type 1 DM: Within one week

Question 4

What eye condition was the focus of the National Programme for Control of Blindness, supported by World Bank assistance from 1994-2001?

Accepted Answer

Cataract

Answer

Refractive errors

Answer

Trachoma

Answer

Vitamin A deficiency

Question 5

What was the goal of the National Programme for Control of Blindness (NPCB) regarding the prevalence of blindness?

Accepted Answer

To reduce it to less than 0.3% by the year 2000

Answer

To reduce it to less than 0.3% by the year 2005

Answer

To reduce it to less than 0.5% by the year 2010

Answer

To reduce it to less than 0.5% by the year 2015

Question 6

The mass treatment of trachoma is undertaken if the prevalence in the community is:

Accepted Answer

5%

Answer

3%

Answer

6%

Answer

10%

Question 7

Minimum visual acuity below which a person is considered blind is:

Accepted Answer

6/18

Answer

6/60

Answer

6/6

Answer

6/12

Question 8

Mass treatment with azithromycin is indicated if the prevalence of follicular trachomatous inflammation (TF) in the 1-9 years population is more than:

Accepted Answer

10%

Answer

4%

Answer

6%

Answer

8%

Question 9

In a school vision screening program, who typically conducts the vision screening?

Accepted Answer

Teacher

Answer

Ophthalmologist

Answer

Optometrist

Answer

NGO worker

Question 10

Mobile eye clinics are an example of which level of prevention?

Accepted Answer

Secondary Prevention

Answer

Primordial Prevention

Answer

Primary Prevention

Answer

Tertiary Prevention

Community Ophthalmology — MCQs

Community Ophthalmology — MCQs

On this page

Practice by Chapter

Want unlimited practice?